Stock Events

Stock Events

Search...

Dynavax Technologies

$11.25

106

-$0.11-0.93% Today

Statistics

Day High

11.4

Day Low

11.22

52W High

15.15

52W Low

9.74

Volume

326,240

Avg. Volume

2,031,280

Mkt Cap

1.47B

P/E Ratio

86.31

Dividend Yield

-

Dividend

-

Upcoming

Earnings

31OctExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-0.19

-0.09

0.02

0.12

Expected EPS

0.11828

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DVAX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Novavax is a direct competitor in the vaccine development space, particularly for COVID-19, where both companies have significant investments.

Moderna is a leader in mRNA vaccine technology, competing with Dynavax's adjuvant technology in developing vaccines for infectious diseases.

Pfizer, with its broad portfolio including COVID-19 vaccines, competes in the same market as Dynavax, especially in vaccine development and distribution.

Johnson & Johnson

Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the vaccine market, including COVID-19, where Dynavax also operates.

GlaxoSmithKline competes with Dynavax in the development of vaccines, including their adjuvant systems used to enhance vaccine efficacy.

Sanofi competes in the vaccine market, including flu vaccines, where Dynavax also has products, making them direct competitors.

AstraZeneca competes with Dynavax in the COVID-19 vaccine space, among other areas, making them significant competitors in pandemic response efforts.

BioNTech, in partnership with Pfizer, competes directly with Dynavax in the COVID-19 vaccine market, leveraging mRNA technology.

CureVac competes in the mRNA vaccine space, similar to Dynavax's involvement in vaccine technology, particularly for infectious diseases.

Analyst Ratings

22$Average Price Target

The highest estimate is $29.

From 2 ratings within the last 6 months. This is not an investment recommendation.

Buy

50%

Hold

50%

Sell

0%

About

Health Technology

Biotechnology

Manufacturing

Pharmaceutical Preparation Manufacturing

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Show more...

CEO

Ryan Spencer

Employees

408

Country

US

ISIN

US2681582019

Listings